Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.

Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A.

Clin Cancer Res. 2019 Aug 1. doi: 10.1158/1078-0432.CCR-19-0138. [Epub ahead of print]

PMID:
31371343
2.

Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer.

Wander SA, Spring LM, Bardia A.

Lancet Oncol. 2019 Jun;20(6):746-748. doi: 10.1016/S1470-2045(19)30279-7. Epub 2019 Apr 27. No abstract available.

PMID:
31036469
3.

p27 transcriptionally coregulates cJun to drive programs of tumor progression.

Yoon H, Kim M, Jang K, Shin M, Besser A, Xiao X, Zhao D, Wander SA, Briegel K, Morey L, Minn A, Slingerland JM.

Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7005-7014. doi: 10.1073/pnas.1817415116. Epub 2019 Mar 15.

4.

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance.

Cornell L, Wander SA, Visal T, Wagle N, Shapiro GI.

Cell Rep. 2019 Mar 5;26(10):2667-2680.e7. doi: 10.1016/j.celrep.2019.02.023.

5.

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.

Spring LM, Wander SA, Zangardi M, Bardia A.

Curr Oncol Rep. 2019 Feb 26;21(3):25. doi: 10.1007/s11912-019-0769-3. Review.

6.

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.

Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, Winer EP, Lin NU, Wagle N.

Nat Genet. 2019 Feb;51(2):207-216. doi: 10.1038/s41588-018-0287-5. Epub 2018 Dec 10.

PMID:
30531871
7.

Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.

Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, Attar E, Hobbs GS, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger DR, Iafrate A, Graubert TA, Stone RM, Fathi AT.

Cancer. 2019 Feb 15;125(4):541-549. doi: 10.1002/cncr.31729. Epub 2018 Nov 13.

PMID:
30422308
8.

Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.

Wander SA, Mayer EL, Burstein HJ.

J Clin Oncol. 2017 Sep 1;35(25):2866-2870. doi: 10.1200/JCO.2017.73.9482. Epub 2017 Jun 3. Review.

PMID:
28580881
9.

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.

Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance NM, Manning AL, Sadrzadeh H, Ballen KK, Attar EC, Graubert TA, Hobbs G, Joseph C, Perry AM, Burke M, Silver R, Foster J, Bergeron M, Ramos AY, Som TT, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Chen YB.

Haematologica. 2017 Apr;102(4):719-727. doi: 10.3324/haematol.2016.158394. Epub 2016 Dec 29.

10.

Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM.

Breast Cancer Res Treat. 2016 Apr;156(2):405-6. doi: 10.1007/s10549-016-3752-9.

11.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS.

Oncologist. 2016 Feb;21(2):214-9. doi: 10.1634/theoncologist.2015-0342. Epub 2016 Feb 1.

12.

Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression.

Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, Howard GA, El-Ashry D, Torné-Poyatos P, Marchal JA, Slingerland JM.

Cancer Res. 2016 Jan 15;76(2):491-504. doi: 10.1158/0008-5472.CAN-15-0927. Epub 2016 Jan 7.

13.

Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.

Fathi AT, Wander SA, Faramand R, Emadi A.

Semin Hematol. 2015 Jul;52(3):165-71. doi: 10.1053/j.seminhematol.2015.03.002. Epub 2015 Mar 17. Review.

PMID:
26111463
14.

Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation.

Zhao D, Besser AH, Wander SA, Sun J, Zhou W, Wang B, Ince T, Durante MA, Guo W, Mills G, Theodorescu D, Slingerland J.

Oncogene. 2015 Oct;34(43):5447-59. doi: 10.1038/onc.2014.473. Epub 2015 Feb 16.

15.

The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.

Wander SA, Levis MJ, Fathi AT.

Ther Adv Hematol. 2014 Jun;5(3):65-77. doi: 10.1177/2040620714532123. Review.

16.

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.

Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM.

EMBO Mol Med. 2013 Oct;5(10):1502-22. doi: 10.1002/emmm.201302558. Epub 2013 Aug 27.

17.

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM.

Breast Cancer Res Treat. 2013 Apr;138(2):369-81. doi: 10.1007/s10549-012-2389-6. Epub 2013 Feb 21. Erratum in: Breast Cancer Res Treat. 2016 Apr;156(2):405-6.

18.

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Wander SA, Hennessy BT, Slingerland JM.

J Clin Invest. 2011 Apr;121(4):1231-41. doi: 10.1172/JCI44145. Epub 2011 Apr 1. Review.

19.

p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.

Wander SA, Zhao D, Slingerland JM.

Clin Cancer Res. 2011 Jan 1;17(1):12-8. doi: 10.1158/1078-0432.CCR-10-0752. Epub 2010 Oct 21. Review.

20.

Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.

Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jordà M, Ju Z, Hennessy BT, Slingerland JM.

Breast Cancer Res Treat. 2011 Jul;128(1):69-78. doi: 10.1007/s10549-010-1024-7. Epub 2010 Jul 29.

PMID:
20669046
21.

p27 as Jekyll and Hyde: regulation of cell cycle and cell motility.

Larrea MD, Wander SA, Slingerland JM.

Cell Cycle. 2009 Nov 1;8(21):3455-61. Epub 2009 Nov 11.

PMID:
19829074
22.

RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.

Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, Smith JA, Slingerland JM.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9268-73. doi: 10.1073/pnas.0805057106. Epub 2009 May 22.

Supplemental Content

Loading ...
Support Center